Allergan has announced that the FDA has awarded approval to its fixed-dose combination antibacterial Avycaaz (ceftazidme and avibactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adult patients. The decision marks the first approval for a gram-negative antibiotic in the US in over 15 years.
Allergan’s Avycaz becomes first FDA-approved gram-negative antibiotic in over 15 years
